CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for MaxCyte Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

MaxCyte Inc
9713 KEY WEST AVENUE, SUITE 400
Phone: (301) 517-5556p:301 517-5556 ROCKVILLE, MD  20850  United States Ticker: MXCTMXCT
Business Summary
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes-Yes-

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
3826 Laboratory analytical instruments
7372 Prepackaged software
7374 Computer processing and data preparation and processing services

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Richard H.Douglas 71 11/3/2021 1/1/2018
President, Chief Executive Officer, Director MaherMasoud 49 1/1/2024 1/1/2020
Chief Financial Officer Douglas J.Swirsky 54 3/27/2023 3/27/2023
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
SeQure Dx, Inc. 1440 MAIN ST SUITE 320 WALTHAM MA United States

Business Names
Business Name
CARMA Cell Therapies, Inc.
CCTI, Inc.
MXCN
MXCR
MXCT
SeQure Dx, Inc.

General Information
Number of Employees: 143 (As of 12/31/2023)
Outstanding Shares: 105,711,093 (As of 12/31/2024)
Shareholders: 35
Stock Exchange: NASD
Federal Tax Id: 522210438
Fax Number: (301) 944-1703
Email Address: info@maxcyte.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, January 31, 2025